Routine Blood Tests Should NOT Be Used to Screen for Cancer Recurrence After Lumpectomy
Do not order routine blood tests (including tumor markers, complete blood counts, or chemistry panels) to screen for breast cancer recurrence in asymptomatic patients with a history of lumpectomy. This recommendation is unequivocal and supported by the highest-quality guidelines from both the American Cancer Society/American Society of Clinical Oncology and multiple international organizations 1, 2.
What Surveillance IS Recommended
The evidence-based surveillance strategy for patients after lumpectomy includes:
Clinical Monitoring
- History and physical examination every 3-6 months for the first 3 years, then every 6-12 months for years 4-5, then annually thereafter 1, 2
- Focus on detecting signs/symptoms of recurrence: new lumps (breast, underarm, neck), rash or skin changes on breast/chest wall, chest pain, changes in breast contour/shape/size, or arm swelling 2
Imaging Surveillance
- Annual mammography of both breasts (the treated breast and contralateral breast) 1, 2
- This is the ONLY routine imaging recommended
- Breast MRI is NOT recommended for routine surveillance unless the patient meets high-risk criteria (lifetime risk >20% for second primary breast cancer, such as BRCA1/BRCA2 mutation carriers or strong family history) 2
Why Blood Tests Are Not Recommended
The rationale against routine laboratory testing is compelling:
Lack of survival benefit: Randomized trials from the 1980s comparing intensive surveillance (including routine blood tests and imaging) versus clinical follow-up alone demonstrated no survival advantage with intensive testing 2. A landmark Italian multicenter RCT of 1,320 women found no difference in overall survival or quality of life between intensive surveillance and clinical follow-up only 3.
High false-positive rates: Routine blood tests show significant false-positive findings that lead to unnecessary additional testing, patient anxiety, and procedures without improving outcomes 2. Studies show that 64% of patients without recurrence had one or more abnormal markers during follow-up 4.
Poor predictive value: Even tumor markers like CEA and CA 15-3 have been shown to detect recurrence much later than clinical symptoms—with mean lead times of -334 days for CEA and -211 days for CA 15-3, meaning they were elevated AFTER recurrence was already detectable by other means 5.
Clinical detection is superior: History and physical examination account for detecting relapse in 95% of patients who recur 4. Symptoms and clinical findings identify recurrence earlier and more reliably than blood tests.
What Tests Should Be Avoided
Specifically, do NOT order routinely in asymptomatic patients:
- Complete blood counts (CBC)
- Comprehensive metabolic panels
- Liver function tests (alkaline phosphatase, SGOT, gamma-GT, bilirubin)
- Tumor markers (CEA, CA 15-3, CA 27.29)
- Bone scans
- Chest X-rays
- CT scans
- PET/CT scans
- Liver ultrasound
When to Order Tests
Blood tests and imaging (beyond mammography) should ONLY be ordered when:
- The patient develops symptoms suggestive of recurrence
- Physical examination reveals abnormal findings
- There is a specific clinical indication based on patient-reported concerns
Common Pitfall to Avoid
The most common error is ordering "routine cancer surveillance labs" because it seems intuitive or because patients request them. Resist this practice. Multiple high-quality studies demonstrate that this approach increases healthcare costs, causes patient anxiety from false-positives, and does not improve survival or quality of life 2, 3. The ESMO 2024 guidelines explicitly state that laboratory tests in asymptomatic patients are "not recommended" with a Grade D recommendation (evidence against use) 7.
Patient Education Priority
Instead of ordering blood tests, educate patients about symptoms that warrant immediate evaluation between scheduled visits. This symptom-directed approach is more effective than routine testing and empowers patients to seek care when truly needed 1, 2.